Persistent genital arousal in women – a new syndrome entity

  title={Persistent genital arousal in women – a new syndrome entity},
  author={David Goldmeier and Sandra Risa Leiblum},
  journal={International Journal of STD \& AIDS},
  pages={215 - 216}
The persistent sexual arousal syndrome (PSAS) is a newly described entity where women become involuntarily aroused genitally for extended periods in time in the absence of sexual desire. Genital vasoengorgement and oedema have been observed. These women are found to be usually very distressed. The cause of the syndrome in the majority of cases is unknown, although a number of women report symptoms after withdrawal from selective serotonin reuptake inhibitors (SSRI) antidepressants. There is no… 
Persistent Genital Arousal Disorder in Women: Case Reports of Association with Anti-Depressant Usage and Withdrawal
Five women are described who believe they developed PGAD either after withdrawing from selective serotonin reuptake inhibitor (SSRI) anti-depressants or while using them, suggesting use of, and withdrawal from, pharmacological agents contributes to the development of PGAD.
Persistent sexual arousal in a woman with associated cardiac defects and raised atrial natriuretic peptide
It is argued that the combined effect of the ASD and fludrocortisone may be associated with an increase in her levels of atrial natriuretic peptide (ANP), and it is postulate that the high serum levels of ANP in her case may be contributory to her PSAS.
Persistent genital arousal disorder following selective serotonin reuptake inhibitor cessation.
A 57-year-old female with a background of anxiety and depression who developed PGAD-like symptoms after cessation of citalopram is reported on.
Restless Genital Syndrome (ReGS) Should Be Distinguished From Spontaneous Orgasms: A Case Report of Cannabis-Induced Spontaneous Orgasm
It was concluded that a 40-year-old woman with persistent spontaneous orgasms were the result of the use of cannabis combined with the long duration of previous sexual activity.
A periclitoral mass as a cause of persistent genital arousal disorder.
Localized causes of persistent genital arousal, though rare, should be included in the differential diagnosis PGAD as detection and treatment can lead to a complete recovery.
A New Medical Treatment With Botulinum Toxin in Persistent Genital Arousal Disorder: Successful Treatment of Two Cases
It is argued that application of Botulinum toxin in the periclitoral region in order to block the dorsal nerve of the clitoris might decrease symptoms of persistent genital arousal disorder.
Female Sexual Arousal
The aims of this brief review are to give definitions of the different types of FSAD, describe their aetiology, prevalence and comorbidity with somatic and psychological disorders, as well as to discuss different medical and psychological assessment and treatment modalities.
Persistent genital arousal in women with pelvic and genital pain.
  • L. Pink, Valérie Rancourt, A. Gordon
  • Medicine, Psychology
    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
  • 2014
Persistent Genital Arousal Disorder
Persistent genital arousal disorder is a condition characterized by spontaneous and often unrelenting sensations of genital arousal in the absence of sexual desire or stimulation that are by definition intrusive, unwanted, and distressing.
Female sexual arousal disorders.
Definitions of the different types of FSAD are given, their aetiology, prevalence and comorbidity with somatic and psychological disorders, as well as to discuss different medical and psychological assessment and treatment modalities are given.


Persistent sexual arousal syndrome: a newly discovered pattern of female sexuality.
Five case descriptions of persistent sexual arousal syndrome are reported, highlighting the essential feature of the syndrome--persistent physiological arousal in the absence of conscious feelings of sexual desire.
Persistent sexual arousal syndrome associated with increased soy intake.
Although no known cause or cure of persistent sexual arousal syndrome has been identified to date, the success of reducing dietary of phytoestrogens in this patient may provide insight into the etiology of the disorder and suggest potential treatments.
Definitions of women's sexual dysfunction reconsidered: Advocating expansion and revision
Based on the review of existing evidence-based research, many modifications to the definitions of women's sexual dysfunctions are recommended and a recommendation is made that all diagnoses be accompanied by descriptors relating to associated contextual factors and to the degree of distress.
Persistent sexual arousal syndrome: a descriptive study.
The results of this research support the description of a condition (persistent sexual arousal) involving involuntary genital and clitoral arousal unrelated to subjective feelings of sexual desire which persists despite one or more orgasms and which usually feels intrusive and unwanted.
Sexual dysfunction in the United States: prevalence and predictors.
The results indicate that sexual dysfunction is an important public health concern, and emotional problems likely contribute to the experience of these problems.
Discontinuation Syndrome in Dysthymic Patients Treated with Selective Serotonin Reuptake Inhibitors
A discontinuation syndrome is common after treatment with SSRIs is stopped in patients with dysthymia, and it appears to be more common in patients receiving paroxetine than in those receiving fluoxettine.
Sexual function problems and help seeking behaviour in Britain: national probability sample survey
The need for estimates of the extent of sexual function problems in the general population has become more urgent given recent debates surrounding the identification and definition of “sexual
Mechanism underlying the therapeutic effects of electroconvulsive therapy (ECT) on depression.
5-HT1A-receptor sensitization may be important for explaining the effectiveness of ECT, as this change induces a decrease in the number of 5-HT2A receptors that are elevated in depressive patients.
Atrial natriuretic peptide: an essential physiological regulator of transvascular fluid, protein transport, and plasma volume.
  • F. Curry
  • Medicine, Biology
    The Journal of clinical investigation
  • 2005
A knockout of the receptor for ANP in vascular endothelia was performed in order to distinguish the effects of ANP-dependent increases in vascular permeability from those of other endocrine actions of AnP in the regulation of plasma volume.